Export to Japan 9: Technical Regulations - Quasi-Drugs

Various EU products and services began to enjoy benefits from the EU-Japan Economic Partnership Agreement (EPA) which entered in force on 1 February 2019, and we are seeing a considerable increase of EU exports to Japan. But yet many EU exporters, particularly small and medium-scaled enterprises (SMEs) perceive access to Japanese market difficult because of unfamiliar trade and business practices.

This is a series of online training which presents the latest market information available in 2020-21 and explain in practical terms the most important things that EU companies should know when exporting to Japan so that the benefits of free trade can become more widely available to EU exporters for the second year of the EU-Japan EPA.

What should you know when entering ‘Quasi Drugs’ market in Japan?

Japan has quasi drugs as an intermediary sector between pharmaceuticals and cosmetics: skin care, make-ups and hair care are the main, large sub-markets of quasi drugs. This webinar assists EU companies, in particular small- and medium sized enterprises (SMEs), in familiarising with this lucrative quasi drug sector and taking business opportunities in exporting EU products to Japan. 

In 30 minutes from your desk, you will understand:

• Definition, Classification, Types of Quasi Drugs
• Markets and Distribution Channels for Quasi Drugs
• Import Procedures for Quasi Drugs – Marketing Approval, Accreditation of Foreign Manufacturers, Regulated Ingredients and Additives, Good Manufacturing Practices(GMP), and Labelling

Programme:

• Introduction
• Expert’s presentation
• Q&A Session

Speaker: Chieko Nakabayashi
Moderator: Pauline Laloux, Business Support Coordinator, EU-Japan Centre
Organiser: EU-Japan Centre for Industrial Cooperation - Brussels Office